「三明治」化疗联合肽受体放射性核素治疗的长期结局:针对FDG与SSTR双阳性侵袭性转移性神经内分泌肿瘤的新策略
本回顾性研究纳入38例FDG与SSTR双阳性侵袭性转移性神经内分泌肿瘤患者,接受「三明治」方案(177Lu-DOTATATE PRRT两周期之间夹入两周期CAPTEM化疗)。中位随访36个月时中位PFS与OS均未达到,36个月PFS率72.5%、OS率80.4%,未出现4级血液学或肾毒性。
要点
- 「三明治」化疗-PRRT在FDG与SSTR双阳性侵袭性NET中显示良好疗效且毒性可控。
- 36个月PFS率72.5%、OS率80.4%,中位PFS与OS未达到。
- 无4级血液毒性及任何级别肾毒性,3级血液学不良事件发生率低。
核心结论
- 「三明治」化疗-PRRT在FDG与SSTR双阳性侵袭性转移性NET患者中取得有利的缓解率、症状控制和较长PFS与OS,且无高级别或危及生命的毒性。
研究设计与样本
- 回顾性研究纳入2012年1月至2018年12月在本机构接受「三明治」化疗-PRRT(PRRT与化疗各至少2周期)的38例FDG与SSTR双阳性侵袭性转移性NET患者。
主要发现
- 症状、生化、分子影像缓解率分别为73%(28例)、39%(15例)、42%(16例),解剖影像缓解17例(45%),基于RECIST 1.1的DCR为84%。
- 治疗前平均ECOG为2.0、KPS为68,治疗后分别变为1.0和75。
- 中位随访36个月时中位PFS与OS均未达到,36个月PFS率72.5%、OS率80.4%。
- 更长PFS与高SSTR摄取、CAPTEM周期数≥7、无骨转移及无既往EBRT暴露相关(P值显著);更高DCR与无骨转移相关(P值显著)。
- 无4级血液毒性及任何级别肾毒性;3级贫血1例(2.5%)、3级血小板减少2例(5%)、3级白细胞减少1例(2.5%)。
关键数值与推荐
- 缓解评估采用预设标准,解剖影像缓解基于RECIST 1.1,DCR为84%。
- 不良事件按CTCAE v5.0分级,未出现4级血液毒性或任何级别肾毒性。
- HRQoL采用ECOG与Karnofsky评分评估。
临床怎么用
- 对于FDG与SSTR双阳性侵袭性转移性NET,「三明治」化疗-PRRT可作为潜在治疗选择,尤其在高SSTR摄取、无骨转移、无既往EBRT暴露及可完成≥7周期CAPTEM的患者中可能延长PFS。
局限性
- 回顾性研究、样本量38例、单中心经验,长期随访数据范围为首次SCPRRT后12至65个月。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The primary aims of this study were to evaluate the long-term outcome of a "sandwich chemo-PRRT (SCPRRT)" regimen with regard to therapeutic response rate, progression-free survival (PFS), and overall survival (OS) rates in metastatic neuroendocrine tumors (NETs) with both somatostatin receptor (SSTR)- and fluorodeoxyglucose (FDG)-avid aggressive disease. Additionally, health-related quality of life (HRQoL) scales, clinical toxicity, and association of PFS and disease control rate (DCR) with various variables were also evaluated. MATERIALS AND METHODS: A total of 38 patients of the aforementioned cohort, who received SCPRRT (at least 2 cycles of each PRRT and chemotherapy) at our institute between January 2012 and December 2018, were included and analyzed in this retrospective study. Between two cycles of 177Lu-DOTATATE peptide receptor radionuclide therapy (PRRT), two cycles of oral capecitabine and temozolomide (CAPTEM) were sandwiched. Therapeutic responses following SCPRRT were assessed by using pre-defined criteria. PFS and OS after first SCPRRT were determined. Eastern Cooperative Oncology Group (ECOG) and Karnofsky score were used for evaluation of HRQoL before and after SCPPRT in all 38 patients. Any adverse events were graded according to the Common Terminology Criteria for Adverse Events version 5.0 (CTCAE v5.0) of the National Cancer Institute. Associations of PFS and DCR with various variables were evaluated. RESULTS: Response (complete response and partial response) to SCPRRT was seen in 28 patients (73%), 15 patients (39%), and 16 patients (42%) on symptomatic, biochemical, and molecular imaging response evaluation criteria respectively. A total of 17 patients (45%) had anatomical imaging response with DCR of 84% based upon the RECIST 1.1 criteria. Pre-therapy mean ECOG and KPS was 2.0 and 68, which changed to 1.0 and 75 respectively following SCPRRT. Long-term follow-up data was available and ranged from 12 to 65 months after the first SCPRRT. Median PFS and OS were not reached at a median follow-up of 36 months. An estimated PFS rate of 72.5% and OS rate of 80.4% was found at 36 months. Longer PFS was dependent upon high SSTR uptake and number of CAPTEM cycle (≥ 7 cycles), absence of skeletal metastasis, and no previous external beam radiotherapy (EBRT) exposure with significant P value. Higher DCR was dependent upon absence of skeletal metastasis with significant P value. SCPRRT was tolerated well with none developing grade 4 hematotoxicity and nephrotoxicity of any grade. Anemia (grade 3), thrombocytopenia (grade 3), and leukopenia (grade 3) were noticed in 1 patient (2.5%), 2 patients (5%), and 1 patient (2.5%) respectively in this study. CONCLUSION: Thus, favorable response rates with effective control of symptoms and longer PFS and OS without high-grade or life-threatening toxicities were important observations in the present study following SCPRRT in NET patients with aggressive, both FDG- and SSTR-avid, metastatic progressive disease. The study results indicate the potential role of "sandwich chemo-PRRT" in future therapeutic algorithms of aggressive, both SSTR- and FDG-positive subset of neuroendocrine tumors.
引用
- Parghane RV, Ostwal V, Ramaswamy A, et al. Long-term outcome of "Sandwich" chemo-PRRT: a novel treatment strategy for metastatic neuroendocrine tumors with both FDG- and SSTR-avid aggressive disease. Eur J Nucl Med Mol Imaging. 2020. PMID: 32876706. doi:10.1007/s00259-020-05004-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。